CA3164063A1 - Methods of treating splenomegaly - Google Patents
Methods of treating splenomegaly Download PDFInfo
- Publication number
- CA3164063A1 CA3164063A1 CA3164063A CA3164063A CA3164063A1 CA 3164063 A1 CA3164063 A1 CA 3164063A1 CA 3164063 A CA3164063 A CA 3164063A CA 3164063 A CA3164063 A CA 3164063A CA 3164063 A1 CA3164063 A1 CA 3164063A1
- Authority
- CA
- Canada
- Prior art keywords
- weeks
- human subject
- bid
- btk inhibitor
- myelofibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Processing Of Solid Wastes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958632P | 2020-01-08 | 2020-01-08 | |
| US62/958,632 | 2020-01-08 | ||
| PCT/US2021/012696 WO2021142257A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3164063A1 true CA3164063A1 (en) | 2021-07-15 |
Family
ID=76788747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3164063A Pending CA3164063A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP3980069A4 (https=) |
| JP (2) | JP7771064B2 (https=) |
| KR (1) | KR20220130151A (https=) |
| CN (1) | CN114423457A (https=) |
| AU (1) | AU2021205484A1 (https=) |
| BR (1) | BR112022013646A2 (https=) |
| CA (1) | CA3164063A1 (https=) |
| CO (1) | CO2022010592A2 (https=) |
| CR (1) | CR20220374A (https=) |
| IL (1) | IL294582A (https=) |
| JO (1) | JOP20220168A1 (https=) |
| MA (3) | MA57226B1 (https=) |
| MX (1) | MX2022008490A (https=) |
| TN (1) | TN2022000185A1 (https=) |
| WO (1) | WO2021142257A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
| TN2022000185A1 (en) * | 2020-01-08 | 2024-04-01 | Telios Pharma Inc | Methods of treating splenomegaly |
| US20240293403A1 (en) * | 2021-06-16 | 2024-09-05 | Telios Pharma, Inc. | Treatment of Symptoms Associated with Myeloproliferative Neoplasms |
| WO2023071973A1 (en) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| WO2024041614A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene Switzerland Gmbh | Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| PL3179991T3 (pl) * | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| WO2016054491A1 (en) * | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112020025881A2 (pt) * | 2018-06-19 | 2021-03-23 | Merck Patent Gmbh | formas cristalinas de 1-(4-{[6-amino-5-(4-fenóxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal do mesmo e processos para obter as mesmas |
| CN109942835A (zh) * | 2019-03-27 | 2019-06-28 | 广州楹鼎生物科技有限公司 | 一种催化分解木质纤维原料的方法 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| TN2022000185A1 (en) * | 2020-01-08 | 2024-04-01 | Telios Pharma Inc | Methods of treating splenomegaly |
-
2021
- 2021-01-08 TN TNP/2022/000185A patent/TN2022000185A1/en unknown
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 MA MA63848A patent/MA63848B1/fr unknown
- 2021-01-08 CA CA3164063A patent/CA3164063A1/en active Pending
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/en active Pending
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/en not_active Ceased
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 MA MA69153A patent/MA69153A1/fr unknown
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
- 2021-01-08 IL IL294582A patent/IL294582A/en unknown
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko active Pending
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/en active Pending
- 2021-01-08 JP JP2022542216A patent/JP7771064B2/ja active Active
-
2022
- 2022-07-07 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
-
2025
- 2025-11-05 JP JP2025186533A patent/JP2026027353A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA57226A1 (fr) | 2023-02-28 |
| JP2023509968A (ja) | 2023-03-10 |
| CO2022010592A2 (es) | 2022-10-31 |
| EP3980069A4 (en) | 2022-08-17 |
| MX2022008490A (es) | 2022-10-13 |
| CN114423457A (zh) | 2022-04-29 |
| MA57226B1 (fr) | 2023-06-28 |
| AU2021205484A1 (en) | 2022-08-18 |
| JOP20220168A1 (ar) | 2023-01-30 |
| KR20220130151A (ko) | 2022-09-26 |
| WO2021142257A1 (en) | 2021-07-15 |
| EP4000624A1 (en) | 2022-05-25 |
| BR112022013646A2 (pt) | 2022-10-04 |
| JP7771064B2 (ja) | 2025-11-17 |
| TN2022000185A1 (en) | 2024-04-01 |
| IL294582A (en) | 2022-09-01 |
| MA69153A1 (fr) | 2025-07-31 |
| EP3980069A1 (en) | 2022-04-13 |
| JP2026027353A (ja) | 2026-02-18 |
| MA63848B1 (fr) | 2024-10-31 |
| MA63848A1 (fr) | 2024-04-30 |
| CR20220374A (es) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4000624A1 (en) | Btk inhibitors for treating splenomegaly | |
| US20260097028A1 (en) | Methods of Treating Myeloproliferative Neoplasms | |
| US20220387434A1 (en) | Combination of a btk inhibitor and an mdm2 inhibitor for cancer treatment | |
| AU2019263064B2 (en) | Methods of treating cancer | |
| TW201922256A (zh) | 治療淋巴樣惡性疾病之方法 | |
| US11642343B2 (en) | Methods of treating splenomegaly | |
| EP4355431A1 (en) | Treatment of symptoms associated with myeloproliferative neoplasms | |
| AU2023390908A1 (en) | Methods of treating myeloproliferative neoplasms | |
| HK40078282A (en) | Btk inhibitors for treating splenomegaly | |
| US20250387383A1 (en) | Methods of treating myeloproliferative neoplasms | |
| HK40112620A (zh) | 喹唑啉酮化合物用於治疗癌症的新用途 | |
| EA045240B1 (ru) | Способы лечения рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240924 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241205 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241231 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241231 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250711 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251107 |